Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Lee Jackson | Apr 20, 2015 at 9:10 AM EDT

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

In a new report, Cowen analysts have sights set on three major pharmaceutical stocks that they expect to have rising…

Jon C. Ogg | Apr 18, 2015 at 11:20 AM EDT

4 Biotech and Pharma Stocks Projected to Rise 50% to 100%

247 Wall St. could not help but notice four analyst calls this past week in which upside of 50% to…

Chris Lange | Apr 18, 2015 at 9:40 AM EDT

5 Big Biotechs Not Keeping Up at All With Hot Biotech Sector in 2015

The health care sector and biotech in particular have been on fire so far in 2015, but some biotech stocks…

Chris Lange | Apr 17, 2015 at 10:50 AM EDT

Akebia Hits New Low After Pricing Secondary Offering

Akebia Therapeutics shares hit a new 52-week low after the company announced the pricing for its secondary offering.

Lee Jackson | Apr 17, 2015 at 10:25 AM EDT

Are Billions About to Be Made in Cosmetic Dermatology by 3 Companies?

While few people may want to admit it, but more and more cosmetic surgery and treatments are being done every…

Lee Jackson | Apr 17, 2015 at 8:20 AM EDT

Huge Biotech Index Rebalance Means Massive Buy Orders for These 4 Stocks

On the close Friday, the NYSE Arca Biotechnology Index is set for a rebalance. These four stocks that could see…

Chris Lange | Apr 16, 2015 at 9:20 AM EDT

UnitedHealth Makes a Push With Earnings

UnitedHealth Group reported better-than-expected first-quarter financial results Thursday before the markets opened.

Paul Ausick | Apr 14, 2015 at 8:45 AM EDT

Johnson & Johnson Slices Forecast as Strong Dollar Hits Revenues

Johnson & Johnson reported better-than-expected first-quarter fiscal 2015 results before markets opened Tuesday morning.

Jon C. Ogg | Apr 13, 2015 at 2:00 PM EDT

Can a Small New Stem Cell Pact Move the Needle for Celgene?

Celgene is one of the world's top biotech stocks now, and its market cap is nearly $100 billion. The company…

Chris Lange | Apr 13, 2015 at 8:35 AM EDT

Short Sellers Increase Their Bets Against Biotech Stocks

The March 31 short interest data have been compared with the March 13 figures, and for most of the selected…

Chris Lange | Apr 10, 2015 at 1:40 PM EDT

Why Mylan Still Has Upside After Perrigo

Independent research firm Argus has weighed in on Mylan and Perrigo prior to the acquisition.

Lee Jackson | Apr 9, 2015 at 9:45 AM EDT

Cowen Thinks 3 Life Science Stocks Can Beat Earnings Estimates

In a new research report, Cowen analysts focus on three life science stocks that they think could beat current consensus…

Chris Lange | Apr 8, 2015 at 1:10 PM EDT

Opposing Views on Gilead Hepatitis C Presentation

Gilead Sciences is a major biotech involved with the EASL conference, and two analysts are calling heads and tails in…

Paul Ausick | Apr 8, 2015 at 12:25 PM EDT

Can Perrigo Get More From Mylan?

Generic drug maker Mylan has proposed to acquire rival Perrigo for $205 per share in cash and stock.

Chris Lange | Apr 7, 2015 at 4:26 PM EDT

What to Expect From Rite Aid Earnings

Rite Aid is scheduled to release its fiscal fourth-quarter financial results Wednesday morning before the markets open.

1 … 265 266 267 268 269 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

4 Biotech and Pharma Stocks Projected to Rise 50% to 100%

5 Big Biotechs Not Keeping Up at All With Hot Biotech Sector in 2015

Akebia Hits New Low After Pricing Secondary Offering

Are Billions About to Be Made in Cosmetic Dermatology by 3 Companies?

Huge Biotech Index Rebalance Means Massive Buy Orders for These 4 Stocks

UnitedHealth Makes a Push With Earnings

Johnson & Johnson Slices Forecast as Strong Dollar Hits Revenues

Can a Small New Stem Cell Pact Move the Needle for Celgene?

Short Sellers Increase Their Bets Against Biotech Stocks

Why Mylan Still Has Upside After Perrigo

Cowen Thinks 3 Life Science Stocks Can Beat Earnings Estimates

Opposing Views on Gilead Hepatitis C Presentation

Can Perrigo Get More From Mylan?

What to Expect From Rite Aid Earnings

Apple Finally Released A Brand-New Siri. Then Its Share Price Cratered.

1 Plain-As-Day Dividend King to Buy and Never Sell That Has Increased Its Payout for 64 Consecutive Years

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old’s Medicare Costs

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old's Medicare Costs

The Roth Conversion That Added $999.60 to a Retiree's Medicare Bill...Two Years Later

Apple Finally Released A Brand-New Siri. Then Its Share Price Cratered.

1 Plain-As-Day Dividend King to Buy and Never Sell That Has Increased Its Payout for 64 Consecutive Years

Health and Healthcare Articles

All Health and Healthcare Articles

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

4 Biotech and Pharma Stocks Projected to Rise 50% to 100%

5 Big Biotechs Not Keeping Up at All With Hot Biotech Sector in 2015

Akebia Hits New Low After Pricing Secondary Offering

Are Billions About to Be Made in Cosmetic Dermatology by 3 Companies?

Huge Biotech Index Rebalance Means Massive Buy Orders for These 4 Stocks

UnitedHealth Makes a Push With Earnings

Johnson & Johnson Slices Forecast as Strong Dollar Hits Revenues

Can a Small New Stem Cell Pact Move the Needle for Celgene?

Short Sellers Increase Their Bets Against Biotech Stocks

Why Mylan Still Has Upside After Perrigo

Cowen Thinks 3 Life Science Stocks Can Beat Earnings Estimates

Opposing Views on Gilead Hepatitis C Presentation

Can Perrigo Get More From Mylan?

What to Expect From Rite Aid Earnings

Apple Finally Released A Brand-New Siri. Then Its Share Price Cratered.

1 Plain-As-Day Dividend King to Buy and Never Sell That Has Increased Its Payout for 64 Consecutive Years

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old’s Medicare Costs

Featured Reads

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old's Medicare Costs

The Roth Conversion That Added $999.60 to a Retiree's Medicare Bill...Two Years Later